Da der er rapporteret tilfælde af hjertebivirkninger med imatinib, bør der foretages en nøje benefit/ risk- vurdering hos HES/ CEL- populationen før påbegyndelse af behandling.
As cardiac adverse events have been reported uncommonly with imatinib, a careful assessment of the benefit/ risk of imatinib therapy should be considered in the HES/ CEL population before treatment initiation.